Susmed (TSE:4263) Research & Development: 円241.2 Mil (TTM As of Dec. 2025)


TSE:4263 Susmed Inc TSE:4263
69 GF Score
Price 円818.00
GF Value 円974.33
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Susmed Research & Development?

Susmed TSE:4263 -2.73% 69 Research & Development is 円241.2 Mil as of Dec. 2025. GuruFocus rates TSE:4263 with a GF Score™ of 69/100 and a GF Value™ of 円974.33 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Susmed's Research & Development for the three months ended in Dec. 2025 was 円0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was 円241.2 Mil.

Susmed  (TSE:4263) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Susmed Research & Development Related Terms

Susmed Research & Development Historical Data

* Premium members only.

The historical data trend for Susmed's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Susmed Research & Development Chart

Susmed Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial 249.14 226.37 176.31 243.35 273.63

Susmed Quarterly Data
Jun20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 68.06 69.92 0.00 171.33
TSE:4263
69GF Score
Susmed Inc TSE:4263
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Susmed Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円241.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円241.2 Mil mean?
Susmed (TSE:4263) has a Research & Development of 円241.2 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Susmed and its competitors.
Is Susmed's Research & Development too high?
Susmed's current Research & Development is 円241.2 Mil. Overall, Susmed has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Susmed's Research & Development compare to VEEV and BTSG?
Susmed's Research & Development of 円241.2 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Susmed and its competitors. Susmed's current Research & Development is 円241.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Modestly Undervalued. The stock's GF Value™ is 円974.33, compared to a current price of 円818.00 — trading 16% below its estimated fair value. The current Research & Development is 円241.2 Mil. Susmed's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Susmed (TSE:4263), the current Research & Development is 円241.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円818.00 is trading 16% below its estimated GF Value™ of 円974.33. GuruFocus considers Susmed to be Modestly Undervalued.

Key valuation signals for TSE:4263:

  • Research & Development: 円241.2 Mil
  • GF Value™: 円974.33 vs. price of 円818.00 (16% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
69GF Score

Get the complete analysis for TSE:4263

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円818.00
Price
円974.33
GF Value